Background: Carbapenems are a class of antimicrobials reserved for resistant infec-
transmitted from nonhuman sources, or bacteria that can acquire resistance genes from nonhuman sources. Carbapenems meet both of these criteria and are therefore classified as "critically important" antimicrobials in human medicine. 1 Carbapenems have a broad spectrum of activity against grampositive and gram-negative aerobes and anaerobes. They are used to treat multidrug resistant (MDR) Enterobacteriaceae infections, including Escherichia coli and Salmonella, 1 and their effectiveness in treating resistant organisms is largely because of their resistance to destruction by beta-lactamases. 2 Because of their importance in treating lifethreatening infections in human and veterinary medicine, judicious use of carbapenems is recommended, and there are multiple sets of guidelines for appropriate use in humans. [3] [4] [5] [6] In human medicine, imipenem-cilastatin is used primarily for hospital-acquired and healthcare-associated pneumonia, intraabdominal infections, neutropenic fever, complicated urinary tract infections (UTIs), polymicrobial necrotizing fasciitis, severe diabetic foot infections, and osteomyelitis. 7 Meropenem is primarily used for skin and soft tissue infections, intra-abdominal infections, acute pancreatitis, obstetric and gynecologic infections, respiratory infections, bacterial meningitis, and febrile neutropenia. 8 Many of the human clinical conditions for which these drugs are used are characterized by high rates of drug resistance or by complicated mixed infections. 3 Meropenem's first reported use in veterinary medicine was in
Brazil in 1999 as a treatment for conjunctivitis. 9 Its spectrum is similar to imipenem, but meropenem is more active against Enterobacteriaceae and less active against gram-positive bacteria. Although not approved for veterinary use, both are prescribed legally in some jurisdictions for extralabel use, primarily for the treatment of resistant infections in dogs and cats, and especially MDR E. coli isolates. 8, 9 There are currently scant data on prescribing patterns and little guidance regarding appropriate use of carbapenems in small animal veterinary medicine.
The goal of this retrospective study was to review cases over the course of 1 year at a veterinary tertiary care hospital in which either imipenem or meropenem was prescribed to cats and dogs, to determine the type of infection they were used to treat and whether the infection was cultured before prescribing a carbapenem, duration of treatment, if antimicrobial treatment was de-escalated with culture results, and survival statistics for dogs and cats in which carbapenems were used. Understanding current prescribing patterns is a first step in providing guidance for and targeting stewardship interventions.
| MATERIALS AND METHODS

| Study design and overview
This is a retrospective study of medical records of dogs and cats over a 1-year period (May 1, 2016, to April 30, 2017 ) at a veterinary tertiary care hospital. The electronic medical record was searched for all cases that were prescribed meropenem or imipenem, and these data were collected: (1) species (dog or cat), (2) reason for hospitalization,
infection type(s), (4) whether the infection was hospital acquired, (5) culture sites, (6) culture and sensitivity results, (7) whether or not treatment was adjusted based on culture results, (8) duration of treatment, and (9) outcome defined as survival to discharge and survival to 1 month after first instance of carbapenem use. were considered statistically significant.
| Data analysis
| Study definitions
When reviewing the data, some dogs and cats had multiple instances of infection. Demographic data are included in Table 1 .
| Reason for hospitalization
In dogs, the most common reasons for hospitalization included pneumonia (32/71, 45%), UTI/pyelonephritis (11/71, 16%), non-specific febrile illness (6/71, 8%), and septic abdomen (3/71, 4.2%). In cats, the most common reasons for hospitalization were UTI/pyelonephritis (5/10) and biliary obstruction (2/10). Other reasons included cholangiohepatitis, pneumonia, and urethral obstruction (each 1/10).
| Infection types
The most common infection type targeted by carbapenem use in dogs was respiratory (34/71, 48%), followed by urinary (19/71, 27%), soft tissue (5/71, 7%), blood/systemic (4/71, 6%), abdominal (4/71, 6%), and other (5/71, 7%). The most common infection type in cats was urinary (6/10) followed by abdominal (3/10) and respiratory (1/10).
There was no significant association between sex and overall type of infection; however, females were significantly more likely to have
UTIs than males in both cats and dogs (P < .03).
| Hospital-acquired Infections
Twelve of 71 (17%) infections in dogs and no infections in cats were hospital acquired. Nine of the 12 (75%) HAIs were aspiration pneumonia and 3/12 (25%) were associated with surgical sites. Four (4/12, 33%) HAIs were classified as XDR, 2/12 (17%) were classified as MDR, and 1/12 (8%) was classified as SDR. No HAIs were classified as NDR.
One (1/12, 8%) HAI returned from culture testing with no bacterial growth, whereas 4/12 (33%) did not have a culture submitted.
| Cultures performed
Cultures were performed in 65/81 (80%) infections. Of the 71 infections involving dogs, 55/71 (78%) were cultured. Of the 10 infections involving cats, all 10 were cultured ( Figure 1 ). As some dogs and cats Of the 115 bacterial isolates tested for susceptibility, 64 (56%)
were tested for susceptibility to carbapenems (56 dogs and 8 cats), 
F I G U R E 1 Flowchart displaying the process of exclusion of infections and isolates from analysis
T A B L E 2 The most common microbial isolates from the 5 most common infection locations in dogs and cats. "Other" included infections in the ear and joints
Location
Number of isolates
Escherichia coli n (%) Fifty-eight gram-negative isolates were tested for carbapenem resis- 
| Duration of use
The duration of carbapenem treatment was not normally distributed, being heavily skewed to the right (Figure 2 Figure 3 ).
Sixty-three of 81 infections (78%) involved the continued administration of a carbapenem after hospital discharge and administered subcutaneously by the caregiver of the pet, including 55/71 (78%)
infections in dogs and 8/10 in cats.
| Survival rates
Fifty-three of 68 animals (78%) survived until discharge. Forty-eight (48/68, 71%) survived to 1 month from their first instance of receiving a carbapenem (Table 2 ). In dogs, 45/58 (78%) survived until discharge and 41/58 (71%) survived over 1 month after first administration of carbapenems. In cats, 8/10 survived until discharge from the hospital and 7/10 survived a month after first administration of carbapenems. When lower tier antimicrobials are used, empirical treatment is often acceptable. At 1 veterinary teaching hospital, the percent of infections for which a second-tier antimicrobial, enrofloxacin, was prescribed in which a culture was performed totaled 55%. For first-tier drugs, such as amoxicillin, cephalexin, or amoxicillin clavulanate, the percent of infections in which a culture was performed averaged only 14%. 19 Although this example only reflects the practices of 1 hospital, it allows us to compare the relative compliance to carbapenem guidelines that state that a bacterial culture must be performed before antimicrobial treatment is initiated. Overall, the percentage of infections treated with carbapenems that were cultured in this study is higher than what has been reported for first-and second-tier antimicrobialtreated infections, which might reflect clinician knowledge and awareness of recommended practices regarding carbapenem use. This might also be reflective of general clinician preferences for obtaining cultures at tertiary care hospitals compared to general practice clinics.
| DISCUSSION
Further insights into the prescribing practices and reasoning of clinicians in regard to carbapenems should be assessed through survey or other methods.
Finally, the data in this study show that dogs and cats treated with carbapenems had high survival rates (Table 4 ). According to the previously mentioned guidelines, carbapenems should be used in dogs and cats with a reasonable expectation of treatment success, and these data support reasonable patient selection practices.
Although no specific recommendations are available for duration of clinical use in veterinary medicine, recommendations for use in humans generally are for short courses, no longer than 7-10 days. 20, 21 Recommendations for antimicrobial use of any kind in humans generally do not exceed 6 weeks. 22 In our study, treatment for only slightly more than 1 quarter of infections involved carbapenems used for 10 days or less, and many of those dogs or cats died before that number could be reached, likely indicating that treatment would have been longer than 10 days. Additionally, many infections were treated longer than the maximum recommendation in human medicine of 6 weeks of treatment. The longest duration of treatment was 196 days for a UTI, which was in a cat that had a history of previous carbapenem use.
Over 3 quarters of infections involved carbapenem use at home, meaning that many dogs and cats were prescribed this drug for long after the time of admission and discharge. In general, infections with isolates in higher AMR classes were treated for longer durations. Most of the infections with susceptibility results had a maximum AMR class of XDR (Table 3) . Based on these data from a single tertiary care facility, the duration of use might be the area for biggest improvement in stewardship. Additional, prospective, multi-institutional data to determine the duration of treatment for various diseases targeted by antimicrobials are needed in veterinary medicine. present, the treatment was adjusted appropriately within the clinician's ability.
Limitations of this study included its small sample size and retrospective nature. Exact reasons for drug prescribing and lack of deescalation were not always apparent from medical record review. 
| Conclusions
This retrospective study of the usage patterns of carbapenems in dogs and cats at a tertiary small animal veterinary hospital showed that clinicians at our hospital are compliant with the recommendations by ISCAID to obtain cultures before carbapenem use and to use these drugs in dogs and cats with a high likelihood of survival. There is room for improvement in reduction of HAIs, duration of treatment, and actively de-escalating treatment regimens that have options other than carbapenems available. Implementation of hospital-level guidelines is effective in reducing the number of antimicrobial prescriptions without influencing patient outcomes. This could be particularly useful in reducing the duration of use of carbapenems in both humans and animals, which might help curb the development of resistance to this crucial drug class. [27] [28] [29] [30] [31] [32] Although there are gaps in our knowledge of the degree to which veterinary prescribing practices influence AMR in humans, the importance of maintaining the effectiveness of carbapenems for lifethreatening human and veterinary infections cannot be denied, and there is evidence to support that carbapenem-resistant bacteria could be easily transferred from animals to humans. 13, 33 This study identifies targets for future research and stewardship interventions for carbapenems in small animal veterinary medicine.
